白癜风皮肤T细胞倾向产生1型和2型细胞因子,通过Jak信号诱导黑素细胞功能障碍和表皮炎症反应
该研究探讨白癜风皮损周围皮肤T细胞分泌组对黑素细胞和表皮细胞的影响。采用NanoString技术和多重ELISA发现活动期白癜风皮损周围皮肤以1型和2型免疫反应为主,T细胞分泌组下调黑素细胞功能并增加炎症因子表达,Jak1/2抑制剂ruxolitinib可抑制这些效应。
要点
- 活动期白癜风皮损周围皮肤同时存在1型和2型免疫反应。
- 白癜风皮肤T细胞分泌组可下调黑素细胞功能并诱导表皮细胞炎症反应。
- Jak1/2抑制剂ruxolitinib可抑制T细胞对表皮细胞和色素的影响。
核心结论
- 白癜风比既往认识更复杂,1型和2型细胞因子共同诱导表皮细胞炎症反应。
- 黑素细胞不仅是T细胞的靶点,还可能主动参与维持炎症。
- Jak抑制剂可阻断T细胞对表皮细胞和色素的影响,具有潜在临床获益。
研究设计与样本
- 使用NanoString技术和多重ELISA检测活动期白癜风皮损周围皮肤及皮肤T细胞分泌组。
主要发现
- 活动期白癜风皮损周围皮肤以显著的1型和2型相关免疫反应为特征。
- 白癜风皮肤T细胞分泌组下调黑素细胞功能和黏附,同时增加黑素细胞线粒体代谢及表皮细胞炎症因子和趋化因子表达。
- Jak1/2抑制剂ruxolitinib强烈抑制上述对表皮细胞的影响。
临床怎么用
- Jak抑制剂可能预防T细胞对表皮细胞和色素的影响,支持其在白癜风中的潜在临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vitiligo is a T cell-mediated inflammatory skin disorder characterized by the loss of epidermal melanocytes. However, the contribution of melanocytes to the physiopathology of the disease in response to the T-cell microenvironment remains unclear. Here, using NanoString technology and multiplex ELISA, we show that active vitiligo perilesional skin is characterized by prominent type 1 and 2 associated immune responses. The vitiligo skin T-cell secretome downregulated melanocyte function and adhesion while increasing melanocyte mitochondrial metabolism and expression of inflammatory cytokines and chemokines by epidermal cells. The Jak1/2 inhibitor ruxolitinib strongly inhibited such effects on epidermal cells. Our data highlight that vitiligo is more complex than previously thought, with prominent combined activities of both T helper type 1- and T helper type 2-related cytokines inducing inflammatory responses of epidermal cells. Melanocytes do not appear only to be a target of T cells in vitiligo but could actively contribute to perpetuate inflammation. Jak inhibitors could prevent the impact of T cells on epidermal cells and pigmentation, highlighting their potential clinical benefit in vitiligo.
引用
- Martins C, Migayron L, Drullion C, et al. Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling. J Invest Dermatol. 2021. PMID: 34655610. doi:10.1016/j.jid.2021.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。